Investors

TauRx is on a mission to discover, develop and commercialise innovative products for the diagnosis, treatment and cure of neurodegenerative diseases caused through protein aggregation

portrait of a asian business leader senior manager standing by window thinking
Thanks to the support of our loyal investors across the globe for a number of years, we have been able to work on tackling one of the world’s most urgent unmet medical needs.

Their continued backing is allowing us to get closer to meeting our target of redefining the future of brain health.

Their support enables our team to conduct groundbreaking research into neurodegenerative disease – leading to a potential new treatment for Alzheimer’s disease, which is currently being assessed by the UK's Medicines and Healthcare products Regulatory Agency (MHRA).

Get in touch today for further information on how you can join the TauRx journey.

Why invest in TauRx?

We welcome enquiries from those who share our vision of transforming the landscape of neurodegenerative disease treatment.

If you're an accredited investor or investment professional seeking more information about TauRx, please use the form below to submit your query. Our investor relations team will review your message and respond promptly with relevant information. We appreciate your interest and look forward to partnering with you in our groundbreaking work.

Nothing on this website constitutes any offer to any person anywhere in the world to sell or an invitation to purchase or tender for any shares, assets or securities. Your attention is drawn to the terms and conditions.

Over 55 million Alzheimer’s patients worldwide. Nearly 140 million predicted by 2050

Nearly 80% of people are concerned about developing dementia

The worldwide cost of dementia is US$1.3 trillion. If dementia was a country, it would be the 17th largest economy in the world

Latest available statistics from Alzheimers Disease International
TauRx Pharmaceuticals Ltd / TauRx Therapeutics Ltd

United Kingdom

Aberdeen - site and mailing office


395 King Street
Aberdeen AB24 5RP
United Kingdom

Asia

Singapore - mailing office


3 Shenton Way
#18-02 Shenton House
Singapore 068805

Singapore - site office


229 Mountbatten Road
#01-05 Mountbatten Square
Singapore 398007